Work

Faculty Opinions recommendation of Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.

Year: 2013

Type: peer-review

Source: Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature

DOI: 10.3410/f.718017565.793478494

Authors: David Salant, Laurence Beck

Institutions: Boston University, Boston Medical Center

Language: English

Topic: Complement system in diseases

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4205729579

Cites:

Cited by:

Related to: 10